Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Jiayue Xi, Ruyue Zhang, Ke Chen, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105848-105848
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
Xingyu Wang, Benoı̂t Gigant, Xi Zheng, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 30
Role of protein degradation systems in colorectal cancer
Zihan Cui, Mingqi Cong, Shengjie Yin, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 11
Development of PROTAC degrader probe of CDK4/6 based on DCAF16
Chunlan Pu, Yuanyuan Liu, Rui Deng, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106637-106637
Closed Access | Times Cited: 18
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies
Govinda R Hancock, Jason Gertz, Rinath Jeselsohn, et al.
Endocrinology (2024) Vol. 165, Iss. 6
Closed Access | Times Cited: 6
Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
Rocío Marisol Espinoza-Chávez, Alessandra Salerno, Anastasia Liuzzi, et al.
ACS Bio & Med Chem Au (2022) Vol. 3, Iss. 1, pp. 32-45
Open Access | Times Cited: 23
Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4
Liquan Zhu, Shiqi Hu, Xiaoqiao Yan, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106461-106461
Closed Access | Times Cited: 16
Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment
Baohua Xie, Bin Xu, Lilan Xin, et al.
Bioorganic Chemistry (2023) Vol. 137, pp. 106590-106590
Closed Access | Times Cited: 11
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Narayanaperumal Pravin, Krzysztof Jóźwiak
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116837-116837
Open Access | Times Cited: 4
Design, synthesis, and biological evaluation of novel PROTACs compounds with good ER α degradation ability
Xianfeng Yang, Xi Zheng, Cheng Liu, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118111-118111
Closed Access
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats
Janis Niessen, Nathalie Arendt, Markus Sjöblom, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2025), pp. 114719-114719
Closed Access
Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2
Chao Wei, Yuhua Li, Lina Guo, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3903-3903
Open Access
Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells
Z. Zhou, Heli Fan, Dehao Yu, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117526-117526
Closed Access | Times Cited: 9
Advanced approaches of developing targeted covalent drugs
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 14
Endo-Lysosomal and Autophagy Pathway and Ubiquitin-Proteasome System in Mood Disorders: A Review Article
Petala Matutino Santos, Giovanna Pereira Campos, Camila Nascimento
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 133-151
Open Access | Times Cited: 6
Conjugation with glucagon like peptide-1 enables targeted protein degradation
Liquan Zhu, Yiyu Zhou, Bei Zhang, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106908-106908
Closed Access | Times Cited: 4
Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells
Biao Hu, Jiantao Hu
Breast Cancer Research and Treatment (2023) Vol. 203, Iss. 2, pp. 383-396
Open Access | Times Cited: 4
Unveiling a new strategy for PDIA1 inhibition: Integration of activity-based probes profiling and targeted degradation
Bei Zhang, Dawei Hong, Hujuan Qian, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107585-107585
Closed Access | Times Cited: 1
How should we teach medicinal chemistry in higher education to prepare students for a future career as medicinal chemists and drug designers? - A teacher´s perspective.
Philipp Klahn
(2024)
Open Access | Times Cited: 1
How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? – A Teacher's Perspective
Philipp Klahn
ChemMedChem (2024)
Open Access | Times Cited: 1
Development of Novel Silicon-Based Hydrophobic Tags (SiHyT) for Targeted Proteins Degradation
Ma Lan, Kun Zhang, Ziqi Huang, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review
André T. S. Vicente, Jorge A. R. Salvador
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 6, pp. 397-420
Closed Access | Times Cited: 2
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Page 1 - Next Page

Scroll to top